Drug intelligence / Profile preview

simvastatin + thymoquinone

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

Simvastatin + thymoquinone is an experimental combination of simvastatin, a cholesterol-lowering HMG-CoA reductase inhibitor, and thymoquinone, the bioactive constituent of Nigella sativa, currently studied for potential anticancer synergism. Simvastatin inhibits the mevalonate pathway, disrupting tumor cell membrane synthesis and proliferation, while thymoquinone exhibits antioxidant, anti-inflammatory, and pro-apoptotic activities. Together, they have demonstrated enhanced apoptosis, cell cycle arrest, and increased cytotoxicity in breast cancer cell lines, particularly when delivered via nanostructured lipid carriers for improved intracellular delivery and efficacy[1][2].

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)

Beyond the preview

Go deeper on simvastatin + thymoquinone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on simvastatin + thymoquinone.

Explore the full profile